Around the dawn of the 20th century, Louis Pasteur discovered the fundamental principle of vaccination: that medicines could prevent disease. However, no one ever thought to apply this principle of primary prevention to psychiatric diseases. Resilience-enhancers are the first preventative psychopharmaceuticals in development. If they successfully translate from the bench to the bedside, resilience-enhancers could protect people predictably at-risk for PTSD and depression: soldiers, firefighters, ER doctors, cancer patients, humanitarian aid workers, refugees—anyone predictably exposed to trauma or major life stress. To learn more, check out Publications & Press, FAQs, and the original research paper.
The Social Outcomes Initiative
US prescription drug spending is on the rise, decreasing medication accessibility and increasing the financial burden on the healthcare system. Much of this cost is driven by the expensive process of new drug development; which can take 10-12 years, cost $1-2 billion per drug, and is highly risky (1:10,000 success rate). Despite the resources invested in the drug development pipeline, many high-burden medical conditions remain unmet needs. The Social Outcomes Initiative (SOI) incentivizes new low-cost treatments for unmet medical needs using novel social impact tools (patent pending). The SOI is incubated by the Jacobs Technion-Cornell Institute at Cornell University, and supported by Helena and Sunrise.
Sunrise is a charitable project whose mission is to prevent, treat, and cure depression. The Sunrise Foundation supports groundbreaking scientific research and emerging interventions, as well as works to expand access to care. Sunrise was co-founded with Dave Morin, motivated in part by his experiences in entrepreneurship, VC, and as co-creator of the Facebook Platform. Learn more here or donate to Sunrise here.